Biogen (NASDAQ:BIIB) Price Target Lowered to $325.00 at Piper Sandler

Biogen (NASDAQ:BIIB – Free Report) had its price objective cut by Piper Sandler from $350.00 to $325.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. BIIB has been the topic of a number of other reports. BTIG Research reaffirmed a […]

Related Keywords

United States ,Germany ,William Blair ,Piper Sandler ,Priya Singhal ,Morgan Stanley ,Baird Financial Group Inc ,Cibc World Market Inc ,Needham Company ,Brown Brothers Harriman Co ,Raymond James Trust ,Biogen Inc ,Vanguard Group Inc ,Free Report ,Moderate Buy ,Get Free Report ,World Market ,Financial Group ,Biogen Daily ,Biogen ,Nasdaq Biib ,Biib ,Medical ,09062x10 ,Lower Price Target ,